BioNTech Founders Launch mRNA Firm; Senator Probes FDA
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Ugur Sahin, co‑founder of BioNTech, will leave the company by year‑end with his wife Özlem Türeci to launch an unnamed mRNA‑focused venture, with BioNTech transferring certain mRNA technology rights and taking a minority stake in the new firm.
- BioNTech will retain its late‑stage cancer pipeline—including antibody‑drug conjugates, immunotherapies, and some mRNA candidates—while continuing to sell its Pfizer‑partnered Covid‑19 vaccine.
- Ron Johnson, Wisconsin senator, announced he will request the FDA’s written denial letters (complete response letters) for rare‑disease drug applications and is considering calling FDA officials, including Commissioner Marty Makary, to testify before his Senate subcommittee.
- The FDA has recently refused to approve several rare‑disease treatments, demanding additional studies before reconsideration, prompting criticism from patient advocates and investors.
- Senator Johnson’s probe aims to increase transparency and accountability at the agency, potentially leading to hearings and further scrutiny of the FDA’s approval process.
Why it matters: The spin‑off gives BioNTech a focused mRNA discovery engine while sharpening its cancer pipeline, directly boosting shareholder value; simultaneously, the Senate investigation forces the FDA to disclose denial rationales, tightening oversight for drug makers and accelerating access for patients awaiting rare‑disease therapies.
Ask SkimNews
